While clinical trials have demonstrated the efficacy of PI3K/Akt/mTOR inhibitors as monotherapy in endometrial cancer (Roncolato et al., 2019; Avila et al., 2022), as of 2024, the European Medicines Agency (EMA) has not granted approval for these inhibitors in endometrial cancer. Here, PIK3CG is linked to endometrial cancer.